Étiquette : cannabis médical

Histoire. La résine de cannabis : remède miracle ou poison d’Orient ?, Le Courrier International, David A Guba Jr.,2019.

Planche botanique de Cannabis sativa tirée du Nordisk familjebok, une encyclopédie suédoise publiée entre 1876 et 1957. Wikicommons Histoire. La résine de cannabis : remède miracle ou poison d’Orient ? David A Guba Jr.11 octobre 2019   XIXe siècle – France. Dans les années 1830, alors que la pandémie de choléra frappe l’Europe, le milieu médical français se passionne pour la résine de cannabis, parée de toutes les vertus. Nombreux sont ceux qui ont applaudi à l’annonce d’un début de réglementation prenant mieux en compte les enjeux de santé publique sur la consommation de cannabis en France. L’Agence nationale de sécurité du médicament a salué les [...]

Lire la suite

Immune Responses Regulated by Cannabidiol, James M. Nichols and Barbara L.F. Kaplan, 2019

Immune Responses Regulated by Cannabidiol James M. Nichols and Barbara L.F. Kaplan Cannabis and Cannabinoid Research, 2019, Volume X, Number X Doi : 10.1089/can.2018.0073   Abstract Introduction : Cannabidiol (CBD) as Epidiolex (GW Pharmaceuticals) was recently approved by the U.S. Food and Drug Administration (FDA) to treat rare forms of epilepsy in patients 2 years of age and older. Together with the increased societal acceptance of recreational cannabis and CBD oil for putative medical use in many states, the exposure to CBD is increasing, even though all of its biological effects are not understood. Once such example is the ability of CBD to be anti-inflammatory and [...]

Lire la suite

Du cannabis dans le PLFSS, Benoît Thelliez, 2019

Du cannabis dans le PLFSS Le député Olivier Véran (LREM, Isère) va défendre un amendement introduisant une expérimentation du cannabis thérapeutique. © FOTOLIA_FABIOBERTI.IT Les choses se pré­cisent. Après que l'Agence na­tio­nale de sé­cu­rité du mé­di­ca­ment et des pro­duits de santé (ANSM) a sous­crit, dé­but juillet 2019, aux pro­po­si­tions du co­mité scien­ti­fique spé­cia­lisé tem­po­raire sur le cadre pra­tique de l’ac­cès au can­na­bis à vi­sée thé­ra­peu­tique en vue d’une ex­pé­ri­men­ta­tion en France, c'est dé­sor­mais le cadre lé­gal qui va être dis­cuté à l'As­sem­blée na­tio­nale. In­vité à l'an­tenne de RTL, le neu­ro­logue et dé­puté de la ma­jo­rité, Oli­vier Vé­ran, a ainsi ex­pli­qué qu'il al­lait pré­sen­ter et dé­fendre un amen­de­ment au pro­jet de loi de fi­nan­ce­ment de la sé­cu­rité so­ciale (PLFSS) pour 2020 vi­sant à mettre en place, au plus vite, une ex­pé­ri­men­ta­tion en mi­lieu hos­pi­ta­lier. Se­lon ses dires, elle de­vrait concer­ner « en­vi­ron 3 000 ma­lades » qui se­ront « sui­vis par des [...]

Lire la suite

Cannabinoids, Endocannabinoids and Cancer, Daniel J. Hermanson and Lawrence J. Marnett , 2011

Cannabinoids, Endocannabinoids and Cancer Daniel J. Hermanson and Lawrence J. Marnett Cancer Metastasis Reviews, 2011, 30, (3-4), 599–612. doi:10.1007/s10555-011-9318-8.   1. Introduction 1.1 Cannabinoid Function Endocannabinoids are bioactive lipids that have a range of interesting activities mediated by two G-protein-coupled receptors (CB1 and CB2) and other putative targets [1-3]. The CB1 receptor is present in the central nervous system and mediates the psychotropic effects of exogenous cannabinoids such as Δ9-tetrahydrocannabinol (THC), the active component of marijuana. In the brain, endocannabinoids and cannabinoids combine with CB1 cannabinoid receptors on axon terminals and regulate ion channel activity and neurotransmitter release [4]. Binding to the CB1 receptor is responsible for [...]

Lire la suite

Opportunities for cannabis in supportive care in cancer, Amber S. Kleckner et al., 2019

Opportunities for cannabis in supportive care in cancer Amber S. Kleckner , Ian R. Kleckner, Charles S. Kamen, Mohamedtaki A. Tejani, Michelle C. Janelsins, Gary R. Morrow and Luke J. Peppone Therapeutic Advances in Medical Oncology, 2019, Vol. 11, 1–29 DOI: 10.1177/1758835919866362   Abstract Cannabis has the potential to modulate some of the most common and debilitating symptoms of cancer and its treatments, including nausea and vomiting, loss of appetite, and pain. However, the dearth of scientific evidence for the effectiveness of cannabis in treating these symptoms in patients with cancer poses a challenge to clinicians in discussing this option with their patients. A review was [...]

Lire la suite

Could Cannabidiol be a Treatment Option for Intractable Childhood and Adolescent Epilepsy ?, Chung Mo Koo et al., 2017

Could Cannabidiol be a Treatment Option for Intractable Childhood and Adolescent Epilepsy ? Chung Mo Koo, Hoon-Chul Kang Journal of Epilepsy Research, 2017, 7, 16-20. pISSN 2233-6249 / eISSN 2233-6257 www.kes.or.kr   Epilepsy is an important disease that affects brain function, particularly in those under 3 years old. Uncontrolled seizures can affect cognitive function and quality of life. For these reasons, many trials have been conducted to investigate treatments for pediatric epilepsy. Currently, many antiepileptic drugs are available for the treatment of epilepsy, but cases of intractable epilepsy continue to exist. In the past, cannabis has been tested as a potential treatment of intractable epilepsy. Since [...]

Lire la suite

Dosage Related Efficacy and Tolerability of Cannabidiol in Children With Treatment-Resistant Epileptic Encephalopathy : Preliminary Results of the CARE-E Study, Richard J. Huntsman et al., 2019

Dosage Related Efficacy and Tolerability of Cannabidiol in Children With Treatment-Resistant Epileptic Encephalopathy : Preliminary Results of the CARE-E Study Richard J. Huntsman, Richard Tang-Wai, Jane Alcorn, Stephanie Vuong, Bryan Acton1,5, Scott Corley, Robert Laprairie, Andrew W. Lyon, Simona Meier, Darrell D. Mousseau, Doris Newmeyer, Erin Prosser-Loose, Blair Seifert, Jose Tellez-Zenteno, Linda Huh, Edward Leung and Philippe Major Frontiers in  Neurology, 2019, 10:716. doi: 10.3389/fneur.2019.00716   Purpose : There is uncertainty regarding the appropriate dose of Cannabidiol (CBD) for childhood epilepsy. We present the preliminary data of seven participants from the Cannabidiol in Children with Refractory Epileptic Encephalopathy (CARE-E) study. Methods : The study is an open-label, [...]

Lire la suite

The protocol for the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study : a phase 1 dosage escalation study, Darren Reithmeier et al., 2018

The protocol for the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study : a phase 1 dosage escalation study Darren Reithmeier, Richard Tang-Wai, Blair Seifert, Andrew W. Lyon, Jane Alcorn, Bryan Acton, Scott Corley, Erin Prosser-Loose, Darrell D. Mousseau, Hyun J. Lim, Jose Tellez-Zenteno, Linda Huh, Edward Leung, Lionel Carmant and Richard J. Huntsman BMC Pediatrics, 2018, 18:221 https://doi.org/10.1186/s12887-018-1191-y   Abstract Background : Initial studies suggest pharmaceutical grade cannabidiol (CBD) can reduce the frequency of convulsive seizures and lead to improvements in quality of life in children affected by epileptic encephalopathies. With limited access to pharmaceutical CBD, Cannabis extracts in oil are becoming increasingly available. [...]

Lire la suite

Cannabidiol attenuates seizures and EEG abnormalities in Angelman syndrome, Bin GU et al., 2019 model mice,

Cannabidiol attenuates seizures and EEG abnormalities in Angelman syndrome model mice. Bin Gu, Manhua Zhu, Madison R. Glass, Marie Rougié, Viktoriya D. Nikolova, Sheryl S. Moy, Paul R. Carney, and Benjamin D. Philpot Journal of Clinical Investigation, 2019 Sep 10, pii: 130419. doi : 10.1172/JCI130419 PMID : 31503547 Abstract Angelman syndrome (AS) is a neurodevelopmental disorder characterized by intellectual disability, lack of speech, ataxia, EEG abnormalities, and epilepsy. Seizures in AS individuals are common, debilitating, and often drug-resistant. Therefore, there is an unmet need for better treatment options. Cannabidiol (CBD), a major phytocannabinoid constituent of cannabis, has antiseizure activity and behavioral benefits in preclinical and [...]

Lire la suite

EC Clears Cannabidiol for Severe Forms of Epilepsy – Medscape -Deborah Brauser,  Sep 23, 2019.

EC Clears Cannabidiol for Severe Forms of Epilepsy Deborah Brauser Medscape Medical News © September 23, 2019   The European Commission (EC) has approved the add-on use of cannabidiol oral solution (Epidyolex, GW Pharmaceuticals) for treating seizures associated with two severe forms of epilepsy, the manufacturer reports. The indication for the drug in the EC's marketing authorization is for use as adjunctive therapy with clobazam (multiple brands) in patients ages 2 and older who have Lennox-Gastaut syndrome (LGS) or Dravet syndrome. As reported by Medscape Medical News, the European Medicine's Agency's (EMA's) Committee for Medicinal Products for Human Use recommended approval for the drug in July. A year earlier, [...]

Lire la suite